Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest milestones, including a successful fundraise and promising results from a repeat-dose dog study.
Leire highlighted strong investor confidence in the company’s mission, following a share issuance that saw enthusiastic participation from long-term shareholders. "We more than doubled our share price with the volume of transactions we have never seen," he noted, citing significant market interest.
The discussion focused on Genflow's long-term strategy to advance gene therapies that target the root causes of ageing. Leire emphasised that the company’s primary focus remains human health, but confirmed growing interest from the animal health sector after encouraging safety data from its dog studies.
Importantly, the repeat dose study showed no adverse reactions, something Leire called a potential "deal breaker" if problems had arisen. “We are quite excited by this result of excellent safety profile, and excellent tolerability with a repeat dose,” he said.
Looking ahead, Genflow expects efficacy data from the ongoing study within five months. Leire also pointed to possible sales or partnerships with animal health companies, especially in professional dog sectors, noting potential economic value in extending working dogs' lives.
The CEO concluded by reaffirming the company’s commitment to turning shareholder trust into results for both patients and investors.
For more company interviews and biotech updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content.
#GenflowBiosciences #Longevity #GeneTherapy #BiotechNews
#AnimalHealth #AgingResearch #DogStudy #LifeExtension
#InvestorUpdate #BiotechInvesting
